ObesityPhase 2NCT05051579

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

A Phase 2 study testing LY3502970 in people with Obesity and Overweight and Obesity, run by Eli Lilly and Company at 35 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight. Read more about this study

Who is it for?: Ages 18 to 75 years
Conditions the study is for: Obesity, Overweight and Obesity
What is being tested?: LY3502970
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 272 participants
Where: 35 sitesin 4 countries
Study dates: 29 Sep 2021to 22 Nov 2022
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Who cannot join

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Show all 14Show fewer

Within 3 months prior to screening:
Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen

Trial locations and contacts

35 sites in 4 countries.

Country

City, postcode or hospital

35 sites in 4 countries

United States18 sites

Anaheim Clinical Trials, LLC
Anaheim, California, 92801
Elite Clinical Trials
Blackfoot, Idaho, 83221
Capital Area Research, LLC
Camp Hill, Pennsylvania, 17011
StudyMetrix Research
City of Saint Peters, Missouri, 63303
John Muir Physician Network Research Center
Concord, California, 94520
Dallas Diabetes Research Center
Dallas, Texas, 75230
Lillestol Research
Fargo, North Dakota, 58104
Diabetes and Thyroid Center of Fort Worth
Fort Worth, Texas, 76132
St. Vincent Hospital d/b/a Prevea Health
Green Bay, Wisconsin, 54303
NorCal Medical Research, Inc
Greenbrae, California, 94904
Rocky Mountain Clinical Research
Idaho Falls, Idaho, 83404
Intend Research, LLC
Norman, Oklahoma, 73069
Valley Clinical Trials, Inc.
Northridge, California, 91325
Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
Pittsburgh, Pennsylvania, 15243
National Clinical Research, Inc
Richmond, Virginia, 23294
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas, 78681
Norcal Endocrinology & Internal Medicine
San Ramon, California, 94583
Premier Research
Trenton, New Jersey, 08611

Other trials in United States

Hungary9 sites

DRC Gyógyszervizsgáló Központ
Balatonfüred, Veszprém megye, 8230
Szent Margit Rendelőintézet Nonprofit Kft
Budapest, 1032
Clinexpert Kft.
Budapest, 1033
TRANTOR'99 Bt. Anyagcsere Centrum
Budapest, 1213
Strazsahegy Medicina Bt.
Budapest, H1171
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032
Bugát Pál Kórház
Gyöngyös, Heves County, 3200
Studium Egeszseghaz Kft
Kalocsa, Bács-Kiskun county, 6300
Kanizsai Dorottya Korhaz
Nagykanizsa, Zala County, 8800

Other trials in Hungary

Canada6 sites

C-health Research
Calgary, Alberta, T2V 4J2
Wharton Medical Clinic
Hamilton, Ontario, L8L 5G8
Alpha Recherche Clinique
Québec, G2J 0C4
ALPHA Recherche Clinique
Québec, G3K 2P8
Centre Médical et Professionnel de l'Ouest de Portneuf
Saint-Marc-des-Carrieres, Quebec, G0A 4B0
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, N7T 4X3

Other trials in Canada

Puerto Rico2 sites

Puerto Rico Medical Research
Ponce, 00717
Research and Cardiovascular Corp.
Ponce, 00717

Other trials in Puerto Rico

About this study

Official title: A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Conditions: Obesity, Overweight and Obesity
Being tested: LY3502970, Placebo
Medical subject headings: Obesity, Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LY3502970Drug
Administered orally
PlaceboDrug
Administered orally

Study groups in NCT05051579
Study group	Role	What they receive
12 milligram (mg) LY3502970	Experimental	Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
24 mg LY3502970	Experimental	Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
36 mg-1 LY3502970	Experimental	Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
36 mg-2 LY3502970	Experimental	Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
45 mg-1 LY3502970	Experimental	Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
45 mg-2 LY3502970	Experimental	Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks. Receives: Drug: LY3502970
Placebo	Placebo comparator	Participants received placebo administered orally once daily until 36 weeks. Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 26

Secondary outcomes (11)

Percent Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 36
Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 26
Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 36
Change From Baseline in Waist Circumference in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 26
Change From Baseline in Waist Circumference in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 36
Change From Baseline in BMI in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 26
Change From Baseline in BMI in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Measured: Baseline, Week 36
Percentage of Participants With >=5% Body Weight Loss
Percentage of participants with >=5% body weight loss was reported.
Measured: Week 26
Percentage of Participants With >=10% Body Weight Loss
Percentage of participants with >=10% body weight loss was reported.
Measured: Week 26
Percentage of Participants With >=5% Body Weight Loss
Percentage of participants with >=5% body weight loss was reported.
Measured: Week 36
Percentage of Participants With >=10% Body Weight Loss
Percentage of participants with >=10% body weight loss was reported.
Measured: Week 36

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

29 Sep 202122 Nov 2022

First posted21 Sep 2021
Study start29 Sep 2021
Primary completion25 Aug 2022
Study completion22 Nov 2022

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (2)Papers the sponsor has linked to this study.
Other trials for ObesityStudies of the same condition, open and under way.
More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 272 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05051579
Sponsor's protocol ID: 18210
Other IDs: J2A-MC-GZGI, 2021-002805-88
Status last verified: Aug 2023
First submitted: 17 Sep 2021
Last updated: 13 Sep 2023
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Publications

Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025 Jun 6;24(1):240. doi: 10.1186/s12933-025-02781-x.
PubMed 40481478
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23.
PubMed 37351564

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

All Obesity trials

Study at a glance

From the registry record, last updated by the sponsor on 13 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
ClinicalTrials.gov ID: NCT05051579
Acronym / sponsor ID: 18210
Conditions: Obesity, Overweight and Obesity
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 272 participants (actual)
Lead sponsor: Eli Lilly and CompanyIndustry (pharma, biotech, devices)
Study start: 29 Sep 2021 (actual)
Primary completion: 25 Aug 2022 (actual)
Study completion: 22 Nov 2022 (actual)
First posted: 21 Sep 2021 (actual)
Results: Posted 13 Sep 2023

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 7

Arm	Type	Receives
12 milligram (mg) LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
24 mg LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
36 mg-1 LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
36 mg-2 LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
45 mg-1 LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
45 mg-2 LY3502970	Experimental	Drug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Placebo	Placebo comparator	Drug: PlaceboParticipants received placebo administered orally once daily until 36 weeks.

Who may qualify

Ages: 18 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Key exclusion criteria (14 listed)

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LY3502970Administered orally	Drug	12 milligram (mg) LY3502970, 24 mg LY3502970, 36 mg-1 LY3502970, 36 mg-2 LY3502970, 45 mg-1 LY3502970, 45 mg-2 LY3502970
PlaceboAdministered orally	Drug	Placebo

Primary outcome

Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Time frame: Baseline, Week 26
Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

11 secondary outcomes

Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Time frame: Baseline, Week 36
Change From Baseline in Body Weight in LY3502970 and Placebo
Time frame: Baseline, Week 26
Change From Baseline in Body Weight in LY3502970 and Placebo
Time frame: Baseline, Week 36
Change From Baseline in Waist Circumference in LY3502970 and Placebo
Time frame: Baseline, Week 26
Change From Baseline in Waist Circumference in LY3502970 and Placebo
Time frame: Baseline, Week 36
Change From Baseline in BMI in LY3502970 and Placebo
Time frame: Baseline, Week 26
Change From Baseline in BMI in LY3502970 and Placebo
Time frame: Baseline, Week 36
Percentage of Participants With >=5% Body Weight Loss
Time frame: Week 26
Percentage of Participants With >=10% Body Weight Loss
Time frame: Week 26
Percentage of Participants With >=5% Body Weight Loss
Time frame: Week 36
Percentage of Participants With >=10% Body Weight Loss
Time frame: Week 36

Results and safety

Results posted to the registry on 13 Sep 2023, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
12 mg LY3502970	50	44
24 mg LY3502970	53	46
36 mg -1 LY3502970	29	27
36 mg -2 LY3502970	29	24
45 mg -1 LY3502970	31	23
45 mg -2 LY3502970	30	28
Placebo	50	43

Primary outcome: Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame: Baseline, Week 26. Least squares mean (Standard Error). Unit: Percent change

Measure	12 mg LY3502970 n = 44	24 mg LY3502970 n = 51	36 mg LY3502970 n = 56	45 mg LY3502970 n = 57	Placebo n = 48
Value	-8.6 (0.85)	-11.2 (0.82)	-12.3 (0.77)	-12.6 (0.75)	-2.0 (0.81)

12 mg LY3502970 vs Placebo: LS Mean difference (Final Values): -6.5 (95% CI -8.9 to -4.2), p <0.001, Mixed Models Analysis
24 mg LY3502970 vs Placebo: LS Mean difference (Final Values): -9.2 (95% CI -11.5 to -6.9), p <0.001, Mixed Models Analysis
36 mg LY3502970 vs Placebo: LS Mean difference (Final Values): -10.2 (95% CI -12.4 to -8.0), p <0.001, Mixed Models Analysis

Population analysed: All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.

11 secondary outcomes are reported in the full results.

Adverse events

Time frame: Baseline through Week 38 (36 weeks with 2 weeks safety follow up). Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
12 mg LY3502970	0 of 50 (0%)	35 of 50 (70%)	0 of 50
24 mg LY3502970	2 of 53 (3.8%)	46 of 53 (86.8%)	0 of 53
36 Mg-1 LY3502970	0 of 29 (0%)	23 of 29 (79.3%)	0 of 29
36 Mg-2 LY3502970	3 of 29 (10.3%)	25 of 29 (86.2%)	0 of 29
45 Mg-1 LY3502970	2 of 31 (6.5%)	26 of 31 (83.9%)	0 of 31
45 Mg-2 LY3502970	0 of 30 (0%)	24 of 30 (80%)	0 of 30
Placebo	0 of 50 (0%)	27 of 50 (54%)	0 of 50

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2023.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40481478Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025 Jun 6;24(1):240. doi: 10.1186/s12933-025-02781-x.
Derived from this study: PubMed 37351564Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23.
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesLink provided by the sponsor.
Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Related trials for Obesity

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director

Eli Lilly and Company

35 sites in 4 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing LY3502970 in people with Obesity and Overweight and Obesity, run by Eli Lilly and Company at 35 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 35 sites in United States, Hungary, Canada, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Sep 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent Change From Baseline in Body Weight in LY3502970 and Placebo (time frame: Baseline, Week 26). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05051579, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2023.